Keywords: Contrast Agents, Vessels
Motivation: Generic ferumoxytol produced in China holds promise in addressing the challenges of evaluating polyvascular disease in patients with chronic kidney disease (CKD). However, its dose-related efficacy and safety as an contrast agent for MR angiography (MRA) in CKD patients require clarification.
Goal(s): To investigate the optimal dose of a generic ferumoxytol for 3T whole-body MRA in CKD patients.
Approach: This prospective, open-label, dose-optimization trial assessed image quality and safety in CKD patients receiving escalating doses (1–4 mg/kg) of generic ferumoxytol.
Results: The 3 mg/kg dose was optimal, demonstrating non-inferiority to the 4 mg/kg dose with a comparable 90-day safety profile.
Impact: This study provides a cost-effective dosing regimen for future Phase III trials and for the clinical screening of polyvascular diseases in CKD patients.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords